In Kenya, a static cohort modelling study evaluated 12 HPV vaccination policy scenarios to inform the country’s cervical cancer elimination trajectory toward 2030. A prompt switch to a single-dose strategy combined with rapid coverage scale-up would avert an additional 249,700 DALYs compared with the current two-dose programme at approximately 50% coverage, while simultaneously reducing both programme costs ($76M vs $81M) and treatment costs ($2.07B vs $2.09B). Switching from a bivalent to a nonavalent single-dose vaccine would avert an additional 26,000 cervical cancer cases (14%), with the $38M incremental vaccination cost offset by $40M in treatment savings — rendering the switch cost-neutral to the health system. An earlier-than-planned Gavi transition (2026 vs 2029) would add $39M in total programme costs, underscoring the importance of contingency planning in the shifting global health financing landscape.